Professor Charlotte Coles
Position: Honorary Clinical Oncology Consultant, Professor of Breast Cancer Clinical Oncology, NIHR Research Professor, Deputy Head of Department of Oncology, Cancer Research UK RadNet Cambridge Lead
Personal home page:
PubMed journal articles - click here
Professor Charlotte Coles is pleased to consider applications from prospective PhD students.
Charlotte Coles is Professor of Breast Cancer Clinical Oncology and NIHR Research Professor at the CRUK Cambridge Centre.
Her research aims are to provide breast cancer patients with the best chance of cure with least side effects by personalising radiation techniques based on risk of recurrence.
She is Chief Investigator of 4 clinical trials with linked translational research:
1. IMPORT LOW: phase III randomised trial (RCT) investigating intensity modulated radiotherapy (IMRT) and partial breast radiotherapy in patients at low risk of recurrence – in follow up: 2018 patients recruited; 71 UK centres
2. IMPORT HIGH: phase III RCT investigating dose-escalated IMRT for patients at higher risk of recurrence - in follow up: 2617 patients recruited; 77 UK centres
3. PRIMETIME: prospective cohort investigating post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers – open: 50+ UK centres to date
4. NEO-RT: feasibility study investigating pre-operative breast IMRT in patients receiving neo-adjuvant hormonal treatment – open: 3 UK centres
Charlotte Coles is lead for Cancer Research UK Radnet-Cambridge Radiation Research Centre of Excellence.
She a National Institute of Health Research (NIHR) Research Professor focussing on risk-adapted breast radiation therapy.
She also Editor-in-Chief of Clinical Oncology journal.
radiotherapy
Symplectic Elements feed provided by Research Information, University of Cambridge
1. Bhattacharya IS, Haviland JS, Kirby AM, Kirwan CC, Hopwood P, Yarnold JR, Bliss JM and Coles CE on behalf of the IMPORT Trialists. Patient reported outcomes over 5 years following whole or partial breast radiotherapy: longitudinal analysis of the IMPORT LOW phase III randomised controlled trial. J Clin Oncol. 2019 Feb 1;37(4):305-317. doi: 10.1200/JCO.18.00982. Epub 2018 Dec 11.
2. Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM, Ciurlionis L, Chan C, Donovan EM, Emson MA, Harnett AN, Haviland JS, Hopwood P, Jefford ML, Kaggwa R, Sawyer EJ, Syndikus I, Tsang YM, Wheatley DA, Wilcox M, Yarnold JR, Bliss JM; IMPORT Trialists. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017 Sep 9;390(10099):1048-1060.
3. MukeshMB, BarnettGC, WilkinsonJS, MoodyAM, WilsonCB, DorlingL, Chan Wah Hak C, QianW, TwymanN, BurnetNG, WishartGC and ColesCE. A randomised controlled trial of Intensity Modulated Radiotherapy (IMRT) for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol. 2013. 31; 36: 4488-95
